--- title: "Weekly Recap | LABU.US -13.92%, fading with the biotech complex" type: "News" locale: "en" url: "https://longbridge.com/en/news/298785287.md" description: "LABU.US fell 13.92% this week to $261.30, while the S&P 500 slipped 0.8%, leaving the ETF about 13.12 percentage points behind the benchmark. The week was a fade from the top: Tuesday opened at $287.83 and touched $300.50 before drifting lower through Thursday, which broke below $270, and Friday closed at the weekly low of $261.30, with a 14.07% intraweek range." datetime: "2026-09-12T04:33:17.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/298785287.md) - [en](https://longbridge.com/en/news/298785287.md) - [zh-HK](https://longbridge.com/zh-HK/news/298785287.md) generator: "portal-rs" --- # Weekly Recap | LABU.US -13.92%, fading with the biotech complex ## The Week LABU.US fell 13.92% this week to $261.30, while the S&P 500 slipped 0.8%, leaving the ETF about 13.12 percentage points behind the benchmark. The week was a fade from the top: Tuesday opened at $287.83 and touched $300.50 before drifting lower through Thursday, which broke below $270, and Friday closed at the weekly low of $261.30, with a 14.07% intraweek range. ## SPDR S&P Biotech This Week The underlying SPDR S&P Biotech (XBI.US) lost 4.65% this week to $156.20, also lagging the S&P 500. It followed a similar pattern: Tuesday opened at $160.765, the high of $163.43 came midweek, and Friday drifted down to $156.20 by the close, for a 4.73% range and a broadly softer tone. ## Leverage & Decay LABU tracks three times the daily move of SPDR S&P Biotech. The underlying dropped 4.65% this week; a simple three-times read gives a theoretical loss of about 13.95%, while LABU actually fell 13.92%, a gap of just 0.03 percentage points. That gap reflects daily rebalancing: the product replicates three times each day’s move, not three times the weekly return. With the underlying trending lower, the single-direction path kept decay small. If price action turns choppy, rebalancing costs would widen and long-term returns can drift away from three times the underlying. ## SPDR S&P Biotech News The sector had a heavy news week. Revolution Medicines’ daraxonrasib approval and NEJM data drew attention, and Veru advanced oral Sabizabulin toward a planned Phase 2 trial. Roivant Sciences picked up buy ratings from Jefferies and TD Cowen after its mosliciguat PHocus data in PH-ILD, while several directors sold shares during the week. A hotter CPI report pushed the market-implied odds of a Fed rate hike at the 16 September meeting to nearly 90%, pressing high-beta biotech names alongside the broader market. ## The Week Ahead The macro calendar dominates. Before the Fed meeting on 16 September, retail sales, the NAHB housing index, and weekly EIA crude inventories will land, and rate-hike expectations are weighing on high-beta exposure. For LABU, the focus is whether SPDR S&P Biotech can stabilise near $156 and how the sector responds to the rate backdrop. ## In Short LABU’s loss this week was nearly three times the underlying’s drop, with minimal decay, showing the product tracked its daily leverage closely in a trending tape. Biotech had clinical news support, but hotter rate expectations and director selling created a crosscurrent, leaving SPDR S&P Biotech lower. The next test is whether the Fed outcome amplifies high-beta swings and whether biotech holds the $156 area. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) ## Related News & Research - [Allworth Financial LP Has $789,000 Stock Position in DuPont de Nemours, Inc. $DD](https://longbridge.com/en/news/298880118.md) - [Baird Financial Group Inc. Sells 187,448 Shares of DuPont de Nemours, Inc. $DD](https://longbridge.com/en/news/298823649.md) - [Comcast Details Split Plan as Broadband, Wireless Competition Intensifies](https://longbridge.com/en/news/298775015.md) - [Electra Therapeutics targets $977.6 million valuation in US IPO](https://longbridge.com/en/news/298906590.md) - [Squarepoint Ops LLC Purchases 268,939 Shares of Lsb Industries Inc. $LXU](https://longbridge.com/en/news/298825051.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**